Cornell Professor Leads New Journal, the First Focused on Nanotubes in Medicine
Launched in March 2012, the journal Nanotube Therapy will be online and open access. It represents the first scientific journal focused on nanotubes, nanorods and nanowires as applied to medicine and biology. The journal’s advisory board is comprised of experts in nanobiotechnology and nanomedicine from around the world, including Prof. Moein Moghimi, Director of the Center for Pharmaceutical Nanotechnology and Nanotoxicology at the University of Copenhagen, who comments: “Devotion of a journal to nanotube biology and medicine is an endorsement of the growing interest in this exciting field and its recognition as an important branch of nanobiotechnology and nanomedicine.”
Nanotube Therapy is a peer-reviewed journal publishing papers on the chemistry, biology, and engineering involved in the application of nanotube technology for the improvement of human health. Material properties, novel devices, in vitro, in vivo, and clinical studies are all within the scope of the journal. Submitted manuscripts utilizing nanotubes for targeted drug delivery, biomaterials, imaging contrast agents, and point-of-care diagnostic assays are all encouraged. Of particular interest is research of a pre-clinical or translational nature that will have a clear impact on the diagnosis and treatment of human disease. James Wemett, CEO of NaturalNano notes, "We see that basic research in this area is becoming increasingly important for commercial applications."
As explained by the journal Editor-In-Chief, Prof. Michael King of Cornell University, “I think it is the right time to establish a new journal with this emphasis. Note, for instance, our recent research showing that nanotubes can be used to easily isolate circulating tumor cells from patient blood samples [Hughes et al., Clin. Chem. 2012]. We are working with an experienced publishing team that has laid out a detailed timeline for achieving indexing of articles in important databases such as PubMed and ISI Web of Science. Versita has committed to waiving all author publishing charges for the first two years, to ensure the success of Nanotube Therapy as an open access journal.”
For more information, check out the Versita website here.